Search - Université Clermont Auvergne Access content directly

Filter your results

14 Results
authFullName_s : O. Tournilhac

Corrigendum to ‘Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers’

G. Fossard , F. Broussais , I. Coelho , S. Bailly , E. Nicolas-Virelizier et al.
Annals of Oncology, 2021, 32 (7), pp.945. ⟨10.1016/j.annonc.2021.04.021⟩
Journal articles hal-03440923v1

Etude de phase II de l’association chemofree obinituzumab et idélalisib dans la maladie de Waldenström en rechute ou réfractaire : résultats de l’analyse intermédiaire, après la phase d’induction

C. Tomowiak , S. Chevret , S. Poulain , C. Herbaux , A. Perrot et al.
40e Congrès de la Société Française d’Hématologie, Sep 2020, Paris, France. 26 (S4), pp.135, 2020, Hématologie
Conference poster hal-02945874v1

Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL

M. van Gelder , O. Tournilhac , D. Te Raa , H.P.J. Visser
Annals of Oncology, 2021, 32 (11), pp.1442-1443. ⟨10.1016/j.annonc.2021.08.1990⟩
Journal articles hal-03440402v1

Prospective, Multicentric Phase II Randomized Trial Comparing the Efficacy of Methotrexate or Cyclophosphamide in Large Granular Lymphocytic Leukemia: A French National Study. Report on the Interim Analysis

T. Lamy , C. Pastoret , R. Houot , Loic Ysebaert , M. Hunault et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1545, 2019, Blood
Conference poster hal-02427556v1

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

C. Kornauth , C. Herbaux , B. Boidol , C. Guillemette , P. Caron et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.3965, 2019, Blood
Conference poster hal-02427551v1

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laetitia Largeaud , Pascale Cornillet-Lefebvre , Jean-François Hamel , Pierre-Yves Dumas , Naïs Prade et al.
Leukemia, 2021, 35 (5), pp.1291-1300. ⟨10.1038/s41375-020-01031-1⟩
Journal articles hal-03441014v1

Aggressive skin cancers in patients who experienced chronic GvHD after allogeneic bone marrow transplantation

A Zampaolo , J. Kanold , O. Tournilhac , F Franck , M Bachelerie et al.
Bone Marrow Transplantation, 2017, 52 (1), pp.130 - 131. ⟨10.1038/bmt.2016.187⟩
Journal articles hal-01655888v1

Evolution du taux de gammaglobulines chez les patients atteints de leucémie lymphoïde chronique traités par ibrutinib

A. Teste , C. Protin , L. Oberic , N. Diop , C. Croizier et al.
40e Congrès de la Société Française d’Hématologie, Sep 2020, Paris, France. 26 (S4), pp.129, 2020, Hématologie
Conference poster hal-02945852v1

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

C. Tomowiak , K. Desseaux , S. Poulain , C. Herbaux , A. Perrot et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. pp.346
Conference papers hal-02418223v1

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

C. Herbaux , C. Kornauth , S. Poulain , O. Tournilhac , M.C. Collins et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. pp.807
Conference papers hal-02418469v1

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

A.S. Michallet , M.S. Dilhuydy , F. Subtil , V. Rouille , B. Mahe et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.3038, 2019, Blood
Conference poster hal-02427562v1

Évolution naturelle des cavernomes portaux non liés à une hépatopathie. Étude rétrospective monocentrique de 32 observations

A.S. Resseguier , M. André , E.A. Orian Lazar , G. Bommelaer , O. Tournilhac et al.
La Revue de Médecine Interne, 2016, 37 (6), pp.394-398
Journal articles hal-02013813v1

Maintien à long terme d’une réponse complète avec maladie résiduelle indétectable après une stratégie de traitement combinant de l’ibrutinib à une immunochimiothérapie ≪ adaptée ≫ chez les patients atteints d’une leucémie lymphoïde chronique non antérieurement traitée

A.S. Michallet , M.S. Dilhuydy , F. Subtil , V. Rouille , B. Mahé et al.
40e Congrès de la Société Française d’Hématologie, Sep 2020, Paris, France. 26 (S4), pp.125, 2020, Hématologie
Conference poster hal-02945820v1
Image document

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laetitia Largeaud , Pascale Cornillet-Lefebvre , Jean-François Hamel , Pierre-Yves Dumas , Naïs Prade et al.
Leukemia, 2021, 35 (5), pp.1291-1300. ⟨10.1038/s41375-020-01031-1⟩
Journal articles hal-03623649v1